Blog Posts
Changes to HSR Premerger Rules Would Add Unnecessary Financial and Operational Barriers to Pro-Innovation M&A
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements that merging parties must meet before a transaction can proceed.
An Interview with AZBio President and CEO on Life Sciences M&A in Arizona
PULSE sat down for a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. PULSE asked Joan for her perspective on how mergers and acquisitions (M&A) have impacted and benefited Arizona’s economic outlook and contributions to the state.
New NAM Report Finds Biopharmaceutical R&D Investment Crucial for Patients, the Economy
In a new report, the National Association of Manufacturers (NAM), a PULSE partner, examines the pharmaceutical industry’s significant commitment to R&D and its impact on our economy and our health.
PULSE Statement on Finalized Joint Merger Guidelines from FTC, DOJ
The Partnership for the U.S. Life Science Ecosystem (PULSE) released the following statement in response to the latest merger guidelines released today by the Federal Trade Commission (FTC) and Department of Justice (DOJ).
Opinion: Proposed regulation would limit life-saving research in Ohio
In a recent op-ed, Ohio Life Sciences President and CEO Eddie Pauline discusses how mergers and acquisitions allow life sciences companies to scale up and provide their research or therapies to patients on a national and global scale.
In Case You Missed It: PULSE Webinar – Life Science M&A: Supporting the Next Generation of Biopharma Breakthroughs
In a recent PULSE webinar, top experts from across the U.S. life sciences ecosystem highlighted the unique importance of mergers and acquisitions (M&A) in bringing new biopharmaceutical breakthroughs to market. The panelists broke down the complex path to market for new treatments and cures, and how M&A is critical in allowing companies of all sizes to combine the necessary resources and expertise to advance these innovations.
The Legislative Pillars Supporting Innovation & Access in the Life Sciences Ecosystem
For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans.
Life Sciences Companies Leverage M&A, Specialized Expertise to Advance Biopharmaceutical Breakthroughs
Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the unique U.S. life sciences ecosystem, fueling diversity, partnerships and efficiencies among innovative companies of all sizes.
Life Sciences Mergers and Acquisitions: A Vital Bridge Across the “Valley of Death”
Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is the so-called “valley of death” – the considerable scientific, regulatory and financial hurdles that life sciences companies must overcome to bring their biopharmaceutical breakthroughs to market.
M&A Provides Vital Bridge for Life Science Innovation Amid Economic Headwinds, Market Demands
In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures.